The notices it replaced
1 notice since 2019, oldest first, each with its awards since FY2014.
- Posted 2019RFA-HL-20-0276 awards
- Posted 2022RFA-HL-23-012This notice, closed · 4 awards
Replaced by RFA-HL-26-018.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 10
- 10 new
- Median first-year cost
- $556,140
- $5,465,806 in all
- Institutions
- 10
- 10 contact PIs
Awards by fiscal year
0
0
0
0
0
0
3
1
2
0
3
1
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- BOSTON CHILDREN'S HOSPITAL1
- CHILDREN'S RESEARCH INSTITUTE1
- INDIANA UNIVERSITY INDIANAPOLIS1
- MASSACHUSETTS GENERAL HOSPITAL1
- MEDICAL UNIVERSITY OF SOUTH CAROLINA1
and 5 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-R (M1))3
- Special Emphasis Panel (ZHL1 CSR-F (M1))2
- Special Emphasis Panel (ZHL1 CSR-F (O1))2
- Special Emphasis Panel (ZHL1 CSR-E (O1))1
- Special Emphasis Panel (ZHL1 CSR-F (J1))1
and 1 other study section
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2025 | Immunocytokine therapy for immune modulation in hemophilia1R33HL177497-01 | Biswas, Moanaro | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $582,638 | Study section ZHL1 |
| FY2024 | Enhancing efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation by CD52 knockout1R33HL175692-01 | Keller, Michael Daniel | CHILDREN'S RESEARCH INSTITUTE, DC | First-year cost $561,030 | Study section ZHL1 |
| FY2024 | RNA-based therapeutics for hemostasis and thrombosis1R33HL173910-01 | Goldfinger, Lawrence EStalker, Timothy J. | THOMAS JEFFERSON UNIVERSITY, PA | First-year cost $546,000 | Study section ZHL1 |
| FY2024 | Peptides for the treatment of pulmonary fibrosis1R33HL175682-01 | Feghali-Bostwick, Carol A. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | First-year cost $464,121 | Study section ZHL1 |
| FY2022 | Developing a Novel E3 Ligase based Anti-inflammatory for ARDS1R33HL157877-01A1 · under RFA-HL-20-027 | Mallampalli, Rama K | OHIO STATE UNIVERSITY, OH | First-year cost $551,250 | Study section ZHL1 |
| FY2022 | Optimization of small molecule integrin activators to enhance cord blood transplant1R33HL161778-01 · under RFA-HL-20-027 | Biediger, Ronald JVanderslice, Peter | TEXAS HEART INSTITUTE, TX | First-year cost $547,028 | Study section ZHL1 |
| FY2021 | Ultrasound-mediated thrombolysis for MVO and PAO treatment.1R33HL156350-01 · under RFA-HL-20-027 | Meuillet, Emmanuelle JoellePacella, John J | MICROVASCULAR THERAPEUTICS, LLC, AZ | First-year cost $575,012 | Study section ZHL1 |
| FY2020 | Novel small molecules to treat degenerative lung and blood diseases1R33HL154133-01 · under RFA-HL-20-027 | Agarwal, Suneet | BOSTON CHILDREN'S HOSPITAL, MA | First-year cost $619,500 | Study section ZHL1 |
| FY2020 | Optimization of PET probe for imaging lung fibrogenesis1R33HL154125-01 · under RFA-HL-20-027 | Caravan, Peter D | MASSACHUSETTS GENERAL HOSPITAL, MA | First-year cost $588,000 | Study section ZHL1 |
| FY2020 | Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension1R33HL154135-01 · under RFA-HL-20-027 | Singh, Jaipal | VASCULONICS, LLC, IN | First-year cost $431,227 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.